Buccal Tablets Market
Report ID: SQMIG35I3423
Report ID: SQMIG35I3423
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35I3423 |
Region:
Global |
Published Date: July, 2026
Pages:
157
|Tables:
151
|Figures:
78
Global Buccal Tablets Market size was valued at USD 342.6 Million in 2024 and is poised to grow from USD 367.95 Million in 2025 to USD 651.37 Million by 2033, growing at a CAGR of 7.4% during the forecast period (2026-2033).
In the global buccal tablet market, solid dosage forms are designed to dissolve in the inner cheek, avoiding first-pass metabolism and providing a direct route for delivering drugs into the systemic circulation. This route is especially important in patients with dysphagia due to rapid onset, increased bioavailability, and ease of self-administration.
Moreover, the rising demand for patient centered fast acting treatments for nausea plus chronic pain is a key driver for the buccal tablets market growth. Buccal fentanyl is being pursued because many clinicians want a substitute to injectable opioids, and the general push is clear. Buccal fentanyl provides near instant pain relief, which in turn lowers the number of hospital visits, strengthens adherence, and it nudges manufacturers to keep refining more advanced mucoadhesive technologies. In addition, the buccal tablets market penetration is also moving forward due to the growth of telemedicine, which makes it easier to use antiemetics such as ondansetron at home, not only in clinics. So, R&D budgets are getting bigger and teams are working on newer formulations with varied compounds. In the end this could open up fresh revenue streams and extend therapeutic coverage, across a broad set of people globally, in many regions.
AI-based formulation optimization is revolutionizing the buccal tablets market outlook through accelerated prediction of drug-polymer interactions, simplified taste masking and improved mucosal adherence. Machine learning algorithms can predict candidate compositions using physicochemical data that would otherwise require lengthy laboratory testing. This reduces costs and accelerates development, allowing producers to respond quickly to changing therapeutic needs. Buccal tablets are gaining popularity due to the easy, non-invasive delivery of both systemic and local drugs. Companies are using AI to develop products that work reliably across different demographics, and to improve patient adherence. This is driving strong market growth.
Market snapshot - (2026-2033)
Global Market Size
USD 342.6 Million
Largest Segment
Analgesics
Fastest Growth
Opioid Dependence Treatments
Growth Rate
7.4% CAGR
To get more insights on this market click here to Request a Free Sample Report
The global buccal tablets market is segmented by drug class, therapeutic application, distribution channel, end user, patient group and region. Based on drug class, the market is segmented into Analgesics, Opioid Dependence Treatments, Hormonal Therapies, Antiemetics and Others. Based on therapeutic application, the market is segmented into Pain Management, Smoking Cessation, Hormone Replacement Therapy, Neurological Disorders and Others. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others. Based on end user, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on patient group, the market is segmented into Pediatric, Adult, Geriatric and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
As per the buccal tablets market analysis, the analgesics segment dominated the market. Consistent with patient preference for non-invasive delivery and physician’s need for rapid therapeutic results, buccal tablets allow for rapid onset of pain relief. Easy delivery bypasses gastrointestinal degradation, thus enhancing bioavailability for acute and chronic pain settings. This functional benefit is driving its widespread acceptance in hospital and homecare, patient compliance and its position as a leader in the buccal tablet market in the overall pharmaceutical space.
However, the opioid dependence segment is predicted to have the largest buccal tablets market share. Buccal tablets allow for a discreet and controlled release of medication to facilitate patient adherence to treatment regimens. Clinical evidence and regulatory support for these delivery channels is growing, which could spur the development of new product pipelines and improve market prospects.
According to the buccal tablets market forecast, the retail pharmacies segment dominated the market as buccal tablets are easily available in physical stores where patients can visit directly, and the pharmacist can give tips that build trust. Its touchable nature invites impulse buying but also provides a chance to educate patients on correct administration, which is vital for adherence. The existing supply chains and reimbursement trends that provide a steady stream of volume and solidify its critical role in many consumer categories of the buccal tablet industry, maintain its dominance.
However, the Online Pharmacies market is the fastest growing segment, as digital channels facilitate the ordering process and enable discreet delivery for patients. The buccal tablet market is witnessing a rapid growth owing to the growing e-commerce logistics and technology integration in telehealth services, which is creating new avenues for product launch and enhancing acceptance.
To get detailed segments analysis, Request a Free Sample Report
As per the buccal tablets market regional forecast, North America has a strong regulatory environment, a well-established pharmaceutical ecosystem and a large number of research institutions focusing on novel dosage forms. The region is home to major multinational corporations with strong manufacturing capabilities and distribution networks, and healthcare providers in the U.S. and Canada are open to patient-centric delivery techniques in particular. Industry-academic collaborations accelerate clinical development and better reimbursement models for therapeutics drive adoption. Increasing consumer awareness of alternate routes of administration is also fuelling demand, making the area a hotbed for new product launches and ongoing advancements in buccal technologies.
United States Buccal Tablets Market
The US buccal tablets industry is supported by a strong clinical trial infrastructure and a proactive regulatory environment that drives the development of new oral delivery systems. Many leading biotech companies have patient outreach programs that educate clinicians about the benefits of buccal administration. Integrated supply networks ensure fast product availability. Increasingly, insurance companies are demanding doctor prescriptions and recognition of therapeutic equivalency. The combination of scientific knowledge, market access and patient engagement continues to fuel strong market momentum.
Canada Buccal Tablets Market
The use of novel medicine delivery systems in Canada’s health system facilitates the market for buccal tablets. Provincial payer policies are becoming increasingly receptive to innovative formulations, and university medical facilities are offering practical evaluation. Proximity to research centers helps domestic firms to convert innovations into marketable products. Patient advocacy groups are actively educating clinicians about the relatively comfortable routes of administration to facilitate the inclusion of buccal tablets into therapeutic regimens across care settings.
Europe is very patient focused and has very strict regulatory harmonization which makes it easier for member countries to approve products. Therapeutic convenience and compliance are favored by healthcare systems thus increases the receptivity of buccal delivery. In Germany, the UK and France, cooperative research networks accelerate formulation innovation. Multinational pharmaceutical companies leverage existing distribution methods to enter different clinical settings. “Reimbursement models that recognize the clinical importance of improved dosage forms will provide another reason for physicians to prescribe. The increasing awareness of various delivery routes by patients and caregivers is aiding to make Europe a vibrant hub for the growth of buccal tablets.
Germany Buccal Tablets Market
The German buccal tablets market share is bolstered by a solid research framework and robust funding for pharmaceutical innovation. Accurate guidelines from regulatory bodies pave the way for successful buccal products and help them enter the market sooner. Physician societies actively promote clinical data on buccal delivery and hospital formularies emphasize evidence-based choices. Domestic companies use precise engineering capabilities to produce high-quality dosage forms, which strengthens the country’s leading position in the European market.
UK Buccal Tablets Market
Patient comfort and clinical outcomes are the key drivers of the UK buccal tablet market and this is reflected in the health technology assessment system. Innovative buccal formulations are piloted closely between academic institutions and industry to accelerate the generation of evidence. Procurement frameworks for the national health service are increasingly including new dosage forms, encouraging widespread use in primary care. Patient advocacy initiatives are enhancing strong market momentum, growing clinician confidence and rising awareness of alternative delivery methods.
France Buccal Tablets Market
In France, the buccal tablet market is expected to expand as healthcare providers recognize the therapeutic benefits of mucosal absorption. Government health agencies are funding research into ways to deliver medicines that are convenient for patients and encouraging partnerships between academic institutions and pharmaceutical companies. Reimbursement programs are gradually expanding to include more cost effective buccal alternatives, also promoting wider physician acceptance. programs for consumer education place a strong emphasis on ease of use especially for populations that have difficulty in swallowing. Consequently, such programmes are becoming more common in the community pharmacy setting.
Asia Pacific enjoys a combination of strong pharmaceutical manufacturing capabilities, fast healthcare modernization and an innovative medication delivery culture. Governments of major economies are seeking to develop patient-centric medicines by providing legislative channels that encourage the use of buccal technology. Increasing prevalence of chronic illnesses and older populations are looking for ways to increase compliance, thus, convenient routes of administration are in a high demand. The best manufacturing infrastructure can be scaled up to deliver high quality and multinational corporations work with regional research groups to develop formulations suited to local preferences. These factors collectively make the region a potential leader in the growth of the global buccal tablet industry.
Japan Buccal Tablets Market
Japan’s healthcare system, which emphasizes patient compliance, supports the buccal tablet market in Japan. Clearly, regulatory agencies are enabling product approvals and guiding mucosal delivery. Strong regional R&D networks partner with participants to adapt formulations to regional treatment needs. Because of the aging population, there is a need for easy-to-use solutions and pharmacists can help educate patients on the use of buccal products. This environment is supporting the buccal tablets market to grow steadily and consistently in all the scenarios.
South Korea Buccal Tablets Market
Favorable regulations and the technologically advanced pharmaceutical industry are driving the growth of the buccal tablet market in South Korea. Big hospitals are using buccal pills to help patients comply, and government incentives are driving the development of new delivery systems. Local producers are pouring money into the high precision production lines to secure product quality at international standards. It collaborates with universities on research projects to develop market adaptable solutions to regional health problems that are constantly evolving.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Increasing Patient Preference For Buccal Delivery
Buccal tablets are absorbed directly via the oral mucosa and do not need to be swallowed. They meet the increasing demand of patients for non-invasive dosage forms, with rapid onset and ease of administration. This desire is what drives pharmaceutical companies to carry out research and development and focus on buccal formulations in their pipelines. Also, the ease of dosage with discretion improves compliance and reduces the side effects of conventional oral tablets and is hence attractive to the elderly and pediatric groups that increase the potential user base and support market expansion.
Advancements In Mucoadhesive Technology
The recent developments in mucoadhesive polymers have increased the residence time of buccal tablets on the oral mucosa, improving absorption of the drug and the establishment of stable therapeutic levels. These technological advances are appealing to developers who want to treat chronic illnesses with tablets with increased medication loading and regulated release profiles. The buccal route has become a more significant area of opportunity and more meaningful product launches are possible with the ability to modify adhesion properties and dissolving profiles for a broader range of chemicals.
Stringent Regulatory Approval Processes
The buccal tablets need to be strictly assessed for safety and efficacy and they need to have a lot of clinical data to show that the bioavailability is consistent and that discomfort is minimal. Often regulatory agencies require a large series of in-vitro and in-vivo studies, thus increasing the time and cost of development. The complexity of filing tactics to comply with different regional regulations discourages smaller businesses from entering the market and reduces the overall rate of new product introduction. This could impede the growth of the buccal tablet industry. This is because investors might be looking to invest in other dosage forms which have relatively simple regulatory procedures.
Higher Manufacturing Complexity Costs
The manufacture of buccal tablets has more technical problems than normal tablets and the polymer blends, moisture and compression forces should be strictly controlled to achieve proper mucoadhesion and drug stability. Capital expenditures are higher due to tight environmental regulations and specialized equipment. Skilled workers are needed for process optimization. These problems are particularly problematic for cost-sensitive markets, where they increase the cost of each unit, thereby reducing the economic competitiveness of buccal products. This suggests that producers may cut production or postpone the launch of new products until they achieve economies of scale.
Request Free Customization of this report to help us to meet your business objectives.
The buccal tablet market is a crowded field with major pharmaceutical players such as AstraZeneca, GSK, Johnson & Johnson, Lilly, MSD, Novartis and Novo Nordisk all vying for their share. These companies are ramping up their M&A activities to invest in proprietary mucoadhesive formulation platforms, form strategic alliances with oral delivery innovators, and gain access to specialty delivery technologies. This is to differentiate their product pipelines and increase market share in fast growing areas.
Top Player’s Company Profile
Recent Developments in the Buccal Tablets Market
In August 2025, Pfizer Inc. applied its knowledge of delivering oral medication to enhance patient compliance and reduce swallowing difficulties with a next-generation buccal tablet platform for rapid onset analgesia. Pfizer may be able to use the platform, which combines taste-masking technology and mucoadhesive polymers, to improve the consistency of therapeutic onset and to meet unmet needs in acute pain management.
In May 2025, Teva Pharmaceutical Industries Ltd. received regulatory approval for its first product, a smoking cessation medication formulated as a buccal tablet. This dosage form is a covert alternative to conventional patches, providing prolonged nicotine absorption through the oral mucosa to increase stop rates.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global buccal tablets market is primarily driven by the need for rapid and non-invasive drug delivery. The analgesics segment accounts for the largest market share as they provide fast pain relief. The second important factor is the continuous development of mucoadhesive technologies, which increase drug residence times and, in turn, allow for increased loading and, therefore, therapeutic options. However, stringent regulatory approval procedures, requiring exhaustive safety and bioavailability data, are impeding business operations, resulting in extended and costly product launches. North America remains the leading region with a developed pharmaceutical ecosystem, strong R&D infrastructure and reimbursement support.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 342.6 Million |
| Market size value in 2033 | USD 651.37 Million |
| Growth Rate | 7.4% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Million |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Buccal Tablets Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Buccal Tablets Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Buccal Tablets Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Buccal Tablets Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Buccal Tablets Market size was valued at USD 342.6 Million in 2024 and is poised to grow from USD 367.95 Million in 2025 to USD 651.37 Million by 2033, growing at a CAGR of 7.4% during the forecast period (2026-2033).
The buccal tablets market is shaped by intense competition among major pharmaceutical groups such as AstraZeneca, GSK, Johnson & Johnson, Lilly, MSD, Novartis and Novo Nordisk, which are accelerating M&A activity to acquire niche delivery technologies, forming strategic partnerships with oral‑delivery innovators, and investing in proprietary mucoadhesive formulation platforms to differentiate their product pipelines and capture emerging market share in fast‑growing regions. 'Pfizer Inc.', 'Teva Pharmaceutical Industries Ltd.', 'Sun Pharmaceutical Industries Ltd.', 'Dr. Reddy's Laboratories Ltd.', 'Cipla Limited', 'Zydus Lifesciences Limited', 'Lupin Limited', 'Aurobindo Pharma Limited', 'Orexo AB', 'Aquestive Therapeutics, Inc.', 'Viatris Inc.', 'Indivior PLC', 'Boehringer Ingelheim International GmbH', 'GlaxoSmithKline plc', 'Sanofi S.A.', 'Bayer AG', 'AstraZeneca plc', 'Johnson & Johnson', 'AbbVie Inc.', 'F. Hoffmann-La Roche Ltd.'
Patients increasingly seek non‑invasive dosage forms that provide rapid onset and ease of administration, and buccal tablets meet these expectations by allowing direct absorption through the oral mucosa without swallowing. This preference drives pharmaceutical companies to prioritize buccal formulations in their pipelines, encouraging investment in research and development. The convenience of discreet dosing also appeals to elderly and pediatric populations, further expanding the potential user base and reinforcing market expansion by offering improved compliance and minimizing side effects associated with traditional oral tablets.
Patient-Centric Delivery Innovation: Patients increasingly prefer dosage forms that offer onset, ease of administration, and minimal swallowing discomfort, driving pharma companies to prioritize buccal tablets as a preferred platform. manufacturers are integrating taste-masking technologies, flexible dosing strengths, and discreet packaging to enhance user experience. This focus on convenience and adherence is reshaping product pipelines, encouraging collaborations with technology firms, and accelerating the launch of formulations that address chronic pain, hormonal therapy, and allergic conditions, thereby expanding the market’s appeal across diverse therapeutic areas.
Why does North America Dominate the Global Buccal Tablets Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
